Form 4: Health In Tech Officer Gains 50,000 Restricted Shares

Health In Tech's Chief AI & Marketing Officer, Dustin Plantholt, acquired 50,000 restricted Class A Common Stock shares tied to a new company initiative.

Summary

• Dustin Plantholt, Chief AI & Marketing Officer of Health In Tech, Inc., acquired 50,000 restricted shares of Class A Common Stock on September 24, 2025.
• These shares were granted under the Health in Tech Equity Incentive Plan.
• The vesting of these shares is performance-based, directly linked to the progress of a new company 'Initiative'.
• One-third (1/3) of the shares will vest in equal monthly installments over a twelve-month period commencing on the date a letter of intent or memorandum of understanding is signed for the Initiative.
• Another one-third (1/3) will vest in equal monthly installments over a twelve-month period commencing on the date the Initiative enters proof-of-concept or beta launch.
• The final one-third (1/3) will vest in equal monthly installments over a twelve-month period commencing on the date of full commercial launch of the Initiative.
• Following this transaction, Mr. Plantholt beneficially owns a total of 64,000 shares of Class A Common Stock, comprising 50,000 restricted and 14,000 unrestricted shares.

Sentiment

Score: 7

Explanation: The grant of performance-based restricted stock to a key officer is a positive step for aligning management incentives with the success of a new company initiative, indicating strategic development. However, the lack of specific detail on the 'Initiative' introduces uncertainty, preventing a higher score.

Positives

• The grant of restricted stock aligns management incentives with company performance and the successful execution of a new 'Initiative'.
• Indicates active development of a new company 'Initiative' which could drive future growth and innovation.
• Increased insider ownership demonstrates confidence in the company's future prospects and strategic direction.

Negatives

• The vesting schedule is entirely dependent on the successful progression and launch of an unspecified 'Initiative', introducing uncertainty regarding the realization of the equity value.
• No immediate cash compensation for the officer from this grant, as shares are restricted and vest over an extended period based on future milestones.

Risks

• The successful development, proof-of-concept, and commercialization of the 'Initiative' are uncertain, directly impacting the vesting of a significant portion of the officer's equity.
• Failure or significant delays in the 'Initiative' could lead to a lack of vesting for the granted shares, potentially affecting management morale, retention, or future strategic direction.
• The specific nature, market potential, and competitive landscape of the 'Initiative' are not disclosed, making it difficult to fully assess the associated business and financial risks.

Future Outlook

The vesting schedule for the restricted shares is directly tied to the future progress and commercial launch of a new company 'Initiative', indicating an expectation of significant development and achievement of key milestones related to this project in the coming years.

Management Comments

• The grant of restricted shares to the Chief AI & Marketing Officer is part of the Health in Tech Equity Incentive Plan, aligning executive compensation with the successful execution of a new company initiative.

Industry Context

Equity incentive plans and performance-based vesting are common practices in the technology and healthcare sectors to attract, retain, and motivate key executives, particularly in companies developing new technologies like AI. This aligns executive interests with long-term company growth and strategic project success, a standard approach in competitive industries.

Comparison to Industry Standards

• Performance-based vesting, particularly tied to project milestones such as a Letter of Intent, proof-of-concept, and commercial launch, is a standard practice in high-growth technology and biotech companies. For instance, companies like Moderna or Palantir often utilize similar structures for R&D or product development leads to incentivize successful project delivery and innovation.
• The structure of vesting in one-third tranches tied to distinct project phases is a common method to mitigate risk and ensure sustained effort throughout the development lifecycle, comparable to how many software development or pharmaceutical companies structure executive bonuses or equity grants for major product rollouts.

Stakeholder Impact

• Shareholders: Potential for increased long-term value if the 'Initiative' is successful, as executive incentives are directly aligned with its achievement.
• Employees: May signal active development and strategic focus within the company, potentially boosting morale and indicating future growth opportunities.
• Management: Provides a strong incentive for the Chief AI & Marketing Officer to drive the success of the 'Initiative' due to direct equity linkage and performance-based vesting.

Next Steps

• Monitoring future company announcements for details regarding the 'Initiative' and its progress towards the outlined milestones (LOI/MOU, proof-of-concept/beta launch, full commercial launch).
• Observing subsequent Form 4 filings for any vesting events or further insider transactions by Dustin Plantholt or other executives.

Key Dates

Recommendation

The grant of performance-based restricted stock to a key executive is a positive indicator of management's commitment to a new strategic initiative and aligns their interests with long-term shareholder value. However, without specific details on the 'Initiative' and its potential market impact, it is difficult to fully assess the upside. The transaction itself is a standard compensation practice and does not provide immediate catalysts for a strong buy, nor does it present significant negative news to warrant a sell. Therefore, a 'hold' recommendation is appropriate, pending further information on the company's strategic 'Initiative'.

Keywords

Health In Tech, HIT, SEC Form 4, Insider Trading, Restricted Stock, Equity Incentive Plan, Executive Compensation, AI, Marketing, Stock Grant